Torion Technologies Inc. Partners with Smiths Detection
Torion Technologies Inc. (American Fork, Utah), a manufacturer of automated miniaturized, hand-portable GC and toroidal ion trap mass spectrometry (TMS) technology, has announced a partnership with Smiths Detection (Danbury, Connecticut), part of the global technology business, Smiths Group and a technology developer and manufacturer of sensors that detect and identify explosives, chemical and biological agents, weapons, and contraband.
Torion Technologies Inc. (American Fork, Utah), a manufacturer of automated miniaturized, hand-portable GC and toroidal ion trap mass spectrometry (TMS) technology, has announced a partnership with Smiths Detection (Danbury, Connecticut), part of the global technology business, Smiths Group and a technology developer and manufacturer of sensors that detect and identify explosives, chemical and biological agents, weapons, and contraband.
According to the companies, the alliance enables the joint development of a next-generation, hand-portable GC-TMS system for the security, defense, and civil emergency responder markets. This technology is designed to identify a variety of substances such as chemical warfare agents (CWAs) and simulants, volatile and semivolatile organic compounds (VOCs and SVs), and other hazardous compounds.
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Navigating the Impact of Funding Cuts: Voices from the Research Community
July 9th 2025Shifts in U.S. federal science funding—driven by the newly established Department of Government Efficiency (DOGE)—are causing delays, uncertainty, and program changes across academic and regulatory research institutions.
FDA Grants Breakthrough Status to AI-Enhanced GC-MS Device for Bladder Cancer Detection
July 1st 2025A new cancer detection test to analyze volatile organic compounds through urine analysis, was granted the Breakthrough Device Designation status by the U.S. FDA. The system, which is built on gas chromatography–mass spectrometry (GC–MS) and proprietary AI, generates real-time cancer risk scores.
